BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ

BioLight today announced that its cancer diagnostics subsidiary, Micromedic Technologies, has identified several new genetic markers with high potential to predict necrosis of the jawbone in patients treated with bisphosphonate drugs and was able to repeat findings from a previous study for one significant marker in a larger and more diversified group tested in a second trial.

Link to complete article

Link to Newsroom

Comments are closed.